Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : Biotechnology Cancer Cures -- Ignore unavailable to you. Want to Upgrade?

To: Jim Oravetz who wrote (200)	11/16/2000 11:48:46 AM
From: scaram(o)uche	Read Replies (1) \| Respond to of 226

Pile of BS. The project may be a good one, not implying that it isn't. However, pile of BS hype. No content. Erwin, if he wants to be forthright, should say... "Dr. Levy previously collaborated with Idec on a similar vaccine strategy. It drove Idec to the brink of bankruptcy. The difference between the LS approach and the Idec approach is XXXXXXXXXXXXX, and the results should therefore differ because XXXXXXXXXXXXXXX."

To: Jim Oravetz who wrote (200)	11/20/2000 6:36:48 PM
From: Jim Oravetz	Read Replies (1) \| Respond to of 226

Matritech Says Colon Cancer Test Detects All Cancer Cases Dow Jones Newswires NEWTON, Mass. -- Matritech Inc. (NMPS) said its technique for detecting colon cancer or pre-cancer polyps was effective in all 17 patients diagnosed with colon cancer, eight patients with polyps and eight patients with benign conditions, including diverticulitis. In a press release Monday, the company said its mass spectometry technique measures the elevation of specific proteins in the blood. Matritech's similar test for bladder cancer is approved for marketing in the U.S., China, Europe and Japan. The company also developed breast cancer and prostate cancer tests using the same technique. Jim